Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan) in metastatic or advanced non-small cell lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS) in patients who had previously received treatment for metastatic NSCLC. Despite this setback, the trial observed a median OS improvement of over three months in a sub-group of patients who were non-responsive to their last prior anti-PD-(L)1 therapy. This distinction did not hold for patients who responded to anti-PD-(L)1 treatment. As a result, Gilead will concentrate on identifying patient populations that could potentially benefit from Trop-2-directed therapy.
The company’s ongoing pipeline includes a Phase III study combining Trodelvy with Merck, Sharp & Dohme’s (MSD; NYSE: MRK) anti-PD-1 drug Keytruda (pembrolizumab) for the treatment of first-line metastatic PD-L1-high NSCLC, as stated in the press release.- Flcube.com
